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Background: During metaphase clathrin stabilises the mitotic spindle kinetochore(K)-fibres. Many anti-mitotic
compounds target microtubule dynamics. Pitstop 2™ is the first small molecule inhibitor of clathrin terminal domain
and inhibits clathrin-mediated endocytosis. We investigated its effects on a second function for clathrin in mitosis.
Results: Pitstop 2 did not impair clathrin recruitment to the spindle but disrupted its function once stationed there.
Pitstop 2 trapped HeLa cells in metaphase through loss of mitotic spindle integrity and activation of the spindle
assembly checkpoint, phenocopying clathrin depletion and aurora A kinase inhibition.
Conclusions: Pitstop 2 is therefore a new tool for investigating clathrin spindle dynamics. Pitstop 2 reduced
viability in dividing HeLa cells, without affecting dividing non-cancerous NIH3T3 cells, suggesting that clathrin is a
possible novel anti-mitotic drug target.
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Cell division (mitosis) results in equal segregation of
duplicated chromosomes into two independent daughter
cells. Premature chromosome segregation (metaphase-
anaphase transition) results in aneuploidy, a hallmark of
many human cancers [1]. This adverse situation is
avoided by activation of the spindle assembly checkpoint
(SAC). This is a signalling pathway consisting of a num-
ber of protein complexes that monitor proper mitotic
spindle assembly, delaying anaphase onset until all chro-
mosomes are stably attached to kinetochores (KTs) [2].
KTs are a large protein assembly around the centromere of
chromosomes that mediates the attachment of chromo-
somes to the spindle microtubules (MTs) so they can
complete segregation. Both SAC activators and inhibitors
are well-known targets for several chemotherapeutic agents.
Drugs that target MTs such as the taxanes and vinca alka-
loids are extensively used for cancer treatment [3]. They* Correspondence: mchircop@cmri.org.au
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reproduction in any medium, provided the orstop APC/C-mediated proteolysis and block anaphase onset
in a SAC-dependent manner. Despite success in the clinic,
drug resistance and toxicity have limited their effectiveness
[3]. Interference with KT assembly, impairment of MT
motors (e.g. dynein) and interference with MT dynamics
also activate the SAC [4]. Thus, a new class of chemothera-
peutics are being developed that specifically target key mi-
totic proteins to either activate or inhibit the SAC, such as
aurora A kinase and kinesin spindle protein, respectively
[3]. These targeted inhibitors prevent proliferation of most
tumour cells in vitro and reduce tumour volume in vivo by
inhibiting growth and/or triggering cell death following
SAC activation/ inhibition [3,4]. Many are in cancer clinical
trials, such as the aurora A protein kinase inhibitor
MLN8054 [5]. They are expected to have a more favourable
therapeutic window than current chemotherapeutic agents
[3], as they would spare non-dividing cells. The anti-cancer
efficacy of these mitotic inhibitors is dependent on their
ability to induce apoptosis following mitotic insult. How-
ever, they do not always result in cell death [6]. Thus, there
is scope for identification of new anti-mitotic targets and
the development of new anti-cancer compounds with
greater efficacy.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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190 kDa clathrin heavy chains (CHCs) arranged in a tri-
mer (called a triskelion) of three “legs” connected by
their C-termini at a central vertex [7,8]. A globular N-
terminal β-propeller domain (TD) is found at the end of
each clathrin leg (i.e. at the N-terminus of the protein
sequence). Clathrin can interact with multiple adapter
proteins like amphiphysin via its TD [9]. Clathrin is best
known for its roles in endocytosis and TGN/ endo-
lysosmal sorting, however, in recent years it has been
assigned another non-trafficking function in mitosis. For
clathrin-mediated endocytosis (CME), clathrin cycles be-
tween the cytoplasmic triskelion and a polymerised coat
on vesicles or membranes. During mitosis, clathrin loca-
lizes to the mitotic spindle [10-12] where it is involved
in organizing and stabilizing spindle MTs [11-13]. It dis-
sociates from MTs during telophase, as the Golgi
reforms to participate in its reassembly [14]. The role of
clathrin at the mitotic spindle is dependent on both its
TD [11] and ability to trimerise as well as its interaction
with TACC3 (transforming acidic coiled-coil-containing
protein 3) [13]. Aurora A kinase phosphorylates and
localises TACC3 to the spindle [15,16]. Phospho-TACC3
recruits clathrin and ch-TOG to the spindle MTs [13]
where they bridge together two or three kinetochore
fibres (K-fibres) to aid chromosome congression [11]
with TACC3 directly interacting with MTs [17,18]. De-
pletion of clathrin by siRNA causes defective chromo-
some congression to the metaphase plate and persistent
SAC activation [11,19-21]. This is analogous to the effect
of aurora A inhibitors which are also SAC activators
[22-26]. Aurora A inhibitors also block clathrin recruit-
ment to the spindle by blocking TACC3 recruitment
[27]. Thus, it is possible that SAC activation and the
anti-cancer properties of aurora A inhibitors may be
partly due to blocking clathrin function at the mitotic
spindle.
Clathrin requires its TD to associate with the mitotic
spindle [11], although the protein(s) mediating its re-
cruitment remains unclear. Preventing this interaction
leads to defective congression of chromosomes to the
metaphase plate and persistent activation of the SAC.
We have recently developed the first small molecule
inhibitors of clathrin, pitstop 1TM and pitstop 2TM, which
target the TD [28]. These two chemically unrelated small
molecules inhibit the association of CHC-TD with cla-
thrin box motif-containing endocytic proteins such as
amphiphysin and AP180/CALM, with no affect on three
other protein-protein interactions or on dynamin
GTPase activity, demonstrating their relative specificity.
Pitstop 2 is a potent inhibitor of transferrin (Tfn) uptake
in cells and is reversible, with CME being fully restored
after a 30 min drug washout, while pitstop 1 is not read-
ily cell permeable. Here, we investigated the effect ofpitstop 2 on mitosis to determine if its ability to block
the TD function in CME is also true for its second func-
tion in the mitotic spindle. We assessed if it possesses
anti-mitotic and anti-cancer properties analogous to
other SAC activating compounds. We report that pitstop
2 induces mitotic phenotypes consistent with inhibition
of clathrin and is anti-proliferative and cytotoxic in a
dividing cancer cell, but not a dividing non-cancer cell.
Our findings provide strong support to the specificity of
pitstop 2 in targeting the TD and indicate that it is a
new member of the SAC activating class of anti-mitotic
compounds. The use of pitstop 2 has revealed that cla-
thrin has the potential to be a new therapeutic target.
Methods
Clathrin, dynamin and aurora kinase inhibitors
Dynole 34–2 and pitstop 2 (in house synthesis) were
prepared as 30 mM stock solutions in 100% DMSO and
stored at −20°C. Pitstop 2 was purified to >98% purity
(HPLC analysis at 254 nm) and NMR 400 MHz H
spectrum in DMSO shows <1% of any other impurity;
NMR 100 MHz C spectrum in DMSO shows <1% of any
other impurity; TLC analysis using a solvent ratio of 9:1
DCM/MeOH shows a single spot visualised by UV.
MLN8237 (Life Research Pty Ltd) was prepared as a
3 mM stock in 100% DMSO and stored at −20°C. Drugs
were diluted directly into RPMI 1640 medium supple-
mented with 10% foetal bovine serum (FBS) and 5%
penicillin/streptomycin (P/S). Pitstop 1TM, Pitstop 2TM,
and PitstopTM trademarks of Freie Universität Berlin,
Children’s Medical Research Institute and Newcastle
Innovation Ltd; Dynole 34-2TM, DynoleTM, Dyngo–4aTM
and DyngoTM are trademarks of Children’s Medical Re-
search Institute and Newcastle Innovation Ltd are they
are available from Abcam BiochemicalsW (Cambridge,
UK).
Cell culture, cell synchronization and drug treatment
HeLa cells were maintained in RPMI 1640 medium sup-
plemented with 10% FBS and 5% P/S and grown at 37°C
in a humidified 5% CO2 atmosphere. For mitotic
synchronization, cells were synchronized at the G2/M
boundary by treatment with the selective cdk1 small-
molecule inhibitor, RO–3306 (9 μM) for 18 h as previ-
ously described [29,30]. Cells were allowed to progress
through mitosis following RO-3306 wash-out. Immedi-
ately following RO-3306 removal (i.e. release from the
G2/M boundary), cells were treated with pitstop 2,
dynole 34–2, MLN8237, drug-free medium or 0.1%
DMSO vehicle.
siRNA oligonucleotides
All specific siRNA oligonucleotides were synthesised by
Invitrogen. Sequences of the siRNAs targeting the
Smith et al. Molecular Cancer 2013, 12:4 Page 3 of 15
http://www.molecular-cancer.com/content/12/1/4indicated proteins are as follows: clathrin heavy chain:
5’-GCAATGAGCTGTTTGAAGA-3’ and epsin 5’-
GGAAGACGCCGGAGTCATT -3’ [12,31]. Luc siRNA,
5’-CGUACGCGGAAUACUUCGATT -3’, was used as a
negative control.Cell transfection
For siRNA analysis, cells were seeded at 50-60% conflu-
ence (6–well plate-1 × 105 cells per well; 12–well plate-
0.2 × 105 cells per well) and transfected with 1000 pmol
of siRNA (per 10 cm dish for immunoblotting), or with
200 pmol (per well of a 6–well plate for immunofluores-
cence microscopy experiments) or 100 pmol (per well of
a 12-well plate for immunofluorescence microscopy
experiments), using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions.Immunoblotting
Cell lysates were prepared as described previously [32]. In
brief, cells were collected by centrifugation, washed with
PBS, then resuspended in ice-cold lysis buffer (20 mM
Tris-HCL (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X–100 and EDTA-free Complete prote-
ase inhibitor cocktail (Roche)) for 30 mins. The supernatant
(cell lysate) was collected following centrifugation at
13,000 rpm for 30 min at 4°C. Cell lysates (50 μg) were frac-
tionated by SDS-PAGE for immunoblot analysis. Anti-
bodies targeting the following proteins were used: cleaved
PARP (Cat No. 9542S, Cell Signalling) and actin (A3854,
Sigma). Antibody bound to the indicated protein was
detected by incubation with a horseradish peroxidase-
conjugated secondary antibody (Sigma). Blotted proteins
were visualised using the ECL detection system (Pierce).Immunofluorescence microscopy
Cells were fixed in ice-cold 100% methanol and
immunostaining was carried out as described previously
[33] using the following antibodies: anti-γ-tubulin
(GTU88; Sigma-Aldrich), and anti-α-tubulin (clone
DM1A, Sigma-Aldrich), anti–Clathrin heavy chain (BD
Biosciences), anti-Centrin 2 (a gift from Eric Nigg) anti-
tubulin (Pan, Cytoskeleton) anti-MAD2 (Covance), anti-
phospho-BubR1S676 (a gift from Sabine Elowe [34]),
anti-HURP (Abcam). Cells were viewed and scored with
a fluorescence microscope (Olympus BX51). Fluorescent
images were captured and processed using an Olym-
pus IX80 inverted microscope using 60× or 100× oil
immersion lenses and Metamorph software. Images
were deconvolved using AutoQuant X2 (AutoQuant
Imaging, Watervliet, NY). Spindle width and cell
width was determined using the line measurement
tool in Metamorph software.MT regrowth after cold depolymerization
Asynchronously growing or metaphase synchronized
cells were placed on ice for 30 min to depolymerize all
MTs. Cells were then incubated at 37°C for 1, 5 or
30 min to allow the MTs to regrow. Cells were then
fixed with ice cold methanol, stained for α-tubulin and
γ-tubulin and fluorescent images were obtained as
described above. The extent of spindle MT regrowth
was assessed by determining the length of the longest
microtubule using deconvolved images and the line
measurement tool in Metamorph software.
Lactate dehydrogenase (LDH) cytotoxicity assay
Cytotoxicity was assayed by determination of lactate
dehydrogenase (LDH) activity. HeLa cells (4000 cells per
well) were seeded in 96 well plates. Asynchronously grow-
ing and G2/M-synchronized cells were treated in triplicate
with pitstop 2, dynole 34–2 or MLN8237 at the indicated
concentration for 20. The supernatant (50 μl) was added to
150 μl of LDH assay reagent (Sigma-Aldrich) and the reac-
tion was allowed to developed for 20 min. Absorbance was
measured at 490 nm and 690 nm (plate background ab-
sorbance). Values were normalised to drug/media back-
ground value and toxicity was calculated as a percentage of
a control cell lysed with 20% Triton–X–100.
Trypan blue exclusion assay
HeLa were seeded in 6-well plates (0.5 × 105 cells per well).
On day 0 (24 h after seeding), cells in duplicate were syn-
chronized at the G2/M boundary by treatment with
RO–3306. Immediately upon mitotic entry (RO–3306
release), cells were treated in the presence or absence of
pitstop 2 or dynole 34–2, at a concentration of 1, 3, 10, 30,
or 100 μM or with MLN8237 at 0.03, 0.3, or 1 μM. After
24 h, the total cell number and viability were measured
using a Vi-CELL XR cell viability analyser as previously
described [30]. Where indicated, cells were treated a second
time with the same compound for an additional 24 h and
then analysed.
NIH3T3 cells were seeded in 6-well plates (0.5 × 105
cells per well). On day 0 (12–16 h after seeding), the
media was replaced with low serum DMEM (0.5% FCS)
to synchronize the cells at the G1/S boundary. After
24 h, the low serum media was replaced with DMEM
containing 10% FCS to allow cells to synchronously
enter the cell cycle. After 10 h, when cells had begun to
enter mitosis, cells were treated and scored for viability
as described above for HeLa cells.
Endocytosis assay
Quantitative high-throughput receptor-mediated endo-
cytosis (RME) assays were performed by an automated
process using Texas Red-Transferrin (T×R-Tfn) as
previously described [35,36] in HeLa cells pre-treated
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34–2 for 30 min. In brief, HeLa cells were grown in
fibronectin-coated (5 μg/mL) 96–well plates. The cells
were serum-starved overnight (16 h) in DMEM minus
FCS then incubated with dynole 34-2, pitstop2 or ve-
hicle for 30 min prior to addition of 4 μg/mL of Tf-×R
for 8 min at 37°C. Cell surface-bound Tfn was
removed by an ice-cold acid wash (0.2 M acetic
acid + 0.5 M NaCl, pH 2.8) for 10 min then rinsed
with ice-cold PBS for 5 min. Cells were immediately
fixed with 4% PFA for 10 min at 37°C. Nuclei were
stained using DAPI. Quantitative analysis of the inhib-
ition of T×R-Tfn endocytosis in HeLa cells was per-
formed on large numbers of cells by an automated
acquisition and analysis system (Image Xpress Micro,
Molecular Devices, Sunnyvale, CA). Nine images were
collected from each well, averaging 40–50 cells per
image. Average integrated intensity of the Tfn signal/
cell was calculated using the IXM software and
expressed as a percentage of DMSO-vehicle treated
control cells. IC50 values were calculated using Prism
5 (GraphPad Software Inc.) and data are expressed as
mean ± 95% confidence intervals (CI) for triplicates
and ~1200 cells.
Results
Pitstop 2 inhibits the mitotic spindle
CHC localises to the mitotic spindle and CHC depletion
results in an increase in mitotic index (i.e. accumulation
of cells at metaphase) with metaphase cells having a col-
lapsed mitotic spindle with a broad metaphase plate
[11]. The mitotic roles for clathrin have been identified
through the use of molecular tools, such as siRNA and
overexpression constructs, that take days to exert their
effects. Therefore, we aimed to confirm a role for cla-
thrin at the mitotic spindle by using the small molecule
clathrin inhibitor, pitstop 2, which penetrates cells and
exerts it biological effect within minutes. To determine
whether pitstop 2 (key compound structures are shown
in Additional file 1: Figure S1) might mimic the effect of
CHC knockdown, HeLa cells were acutely treated for
6 h with pitstop 2. The mitotic index increased signifi-
cantly (Figure 1A), suggesting that it activates the SAC.
The effect on mitotic index was concentration-
dependent, being significant at concentrations as low as
0.01 μM. At 100 μM, 14.0 ± 0.02% of the cells were in
metaphase, compared to 4.4 ± 0.6% of control cells
(treated with the vehicle, DMSO). A similar effect was
observed after treatment with the Aurora A protein kin-
ase inhibitor, MLN8237, (15.5 ± 2.3%; Figure 1A), which
is a SAC activator with an unrelated chemical scaffold.
To ask whether the pitstop-mediated phenotype was due
to targeting the TD of CHC, we tested its ability to alter
the mitotic index of CHC-depleted cells using siRNA,which depleted this protein by >90% as we have previ-
ously characterised (Smith, 2012 21118 /id; Additional
file 2: Figure S2). As previously reported [11], the mitotic
index of CHC-depleted cells was significantly elevated
(10.9 ± 0.8% vs 3.1 ± 0.7% for untreated control cells;
Figure 1B). Treatment of CHC-depleted cells with pit-
stop 2 did not have any additional effects, nor did the
dynamin inhibitor, dynole 34-2TM, which exclusively dis-
rupts cytokinesis [37]. MLN8237 had no further effects
(Figure 1B), consistent with the idea that clathrin acts
downstream of Aurora A. Thus pitstop 2 disrupts HeLa
cells from completing metaphase, consistent with inhib-
ition of the TD of CHC and SAC activation.
We next analysed mitotic spindle phenotypes induced
by pitstop 2 in more detail (Additional file 3: Figure S3).
The width of the mitotic spindle at the cell equator was
reduced in 54.6 ± 11.3% of metaphase cells treated with
pitstop 2 (100 μM) as revealed by immunofluorescence
microscopy analysis (Figure 1C and D). These spindles
appeared to contain less MT fibres (Figure 1C). The
narrow or collapsed mitotic spindle phenotype was
observed in a significant number of metaphase cells at
pitstop 2 concentrations as low as 0.01 μM. An analo-
gous phenotype was observed following exposure to
MLN8237 (Figure 1C and D), as previously reported
[38]. Metaphase cells depleted of CHC also had a
collapsed mitotic spindle (47.1 ± 5.0% vs 10.9 ± 1.4% for
control cells; Figure 1C and E). In contrast, inhibition of
dynamin with dynole 34-2 (30 μM, Figure 1C and D) or
depletion by siRNA of another endocytic protein, epsin,
that also has a role in metaphase (Additional file 2:
Figure S2) [39], did not collapse the spindle (Figure 1C
and E). The extent of mitotic spindle collapse was quan-
tified as a ratio of the spindle width:total cell width at
the cell equator and was unaffected by dynole 34–2 or
epsin siRNA (Figure 1F and G). Pitstop 2, MLN8237 and
CHC siRNA all reduced the ratio from 6.5 to <0.4
(Figure 1F and G). Pitstop 2 did not further reduce this
ratio after CHC siRNA treatment (Figure 1G), again sup-
porting that pitstop action is mediated via clathrin. As
previously reported [11], in cells depleted of CHC there
is a broader metaphase plate (13.6 μm vs 5.6 μm in con-
trol cells; Figure 2A) indicative of clathrins’ role in
chromosome congression. Pitstop 2 (13.9 μm) and
MLN8237 (12.6 μm produced an analogous phenotype,
Figure 2B) and again pitstop 2 had no additional effect
in CHC-depleted cells (Figure 2A).
We next asked whether the reduced number of mitotic
spindle fibres observed in pitstop 2–treated metaphase cells
was due to disruption of K-fibres. CHC stabilizes the mi-
totic spindle by specifically bridging K-fibres [11,17,18]. As
would be predicted from this, we found that metaphase
cells depleted of CHC also have abnormal staining of the
K-fibre marker, hepatoma upregulated protein (HURP;
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39.2 ± 4.6% of metaphase cells (Figure 2C and E).
MLN8237 and epsin depletion also disrupted HURP stain-
ing (Figure 2C-E), while dynole 34–2 had no effect
(Figure 2C and E). Therefore pitstop 2 disrupts mitotic
spindle organisation by disrupting K-fibres, resulting in
impaired chromosome congression to the metaphase plate.
The mitotic effects induced by pitstop 2 cannot be
attributed to a block in endocytosis as both pitstop 2
and dynole 34–2 blocked uptake of transferrin in a dose-
dependent manner (Additional file 4: Figure S4), as
previously reported [28,35]. However only pitstop 2
disrupted the mitotic spindle and chromosome align-
ment (Figure 1 and 2). This is consistent with the
mitotic role of CHC being known to be independent of
its endocytic function [11].
Pitstop 2 induces multipolar spindles and loss of centriole
cohesion
Depletion of CHC increases the frequency of multipolar
spindles in 32.0 ± 3.6% of cells (Figure 3A and C), as
previously reported [40]. Pitstop 2 also induced multi-
polar spindles in 26.4 ± 3.4% of metaphase cells vs 6.4 ±
3.1% or 9.6 ± 2.5% for untreated or vehicle-treated cells
(Figure 3A and B). The spindle pole (or centrosomes) of
a metaphase cell is the site of microtubule nucleation
and is composed of a mother and daughter centriole,
surrounded by pericentriolar matrix (PCM) [41]. Pitstop
2 treatment reduced the number of centrioles to one in
a significant number of spindle poles (26.8 ± 1.0% vs
6.0 ± 2.1% of control cells; Figure 3A and D). This action
was phenocopied in cells depleted of CHC (24.2 ± 3.9%;
Figure 3A and E), suggesting that CHC contributes to
centriole cohesion. MLN8237 treatment caused an
analogous phenotype (Figure 3A and D), consistent with
a previous report [42], yet dynole 34-2 did not affect
bipolar spindle formation (Figure 3A and B) or centriole
cohesion (Figure 3A and D). Therefore clathrin TD
inhibition via pitstop 2 causes multipolar spindles due to
a loss of centriole cohesion, indicating that clathrin has
an additional metaphase function in maintaining spindle
pole integrity.
Pitstop does not impair clathrin-dependent mitotic
spindle regrowth
Our next goal was to determine if the action of pitstop 2
at the spindle was mediated by its TD. A complex of
phospho-TACC3 and ch-TOG is known to recruit
clathrin to the mitotic spindle and that the trimeric
complex is required for both assembly and stability of
the spindle [27]. Phospho-TACC3 binds CHC via its
linker domain and first CHC repeat and this interaction
does not appear to require the TD of clathrin [13].
Therefore, the initial stage of spindle assembly requiresCHC but may not require the function of its TD at this
time point, and thus would be expected to be pitstop 2–
resistant. We approached this by assessing the rapid
spindle MT regrowth that occurs following cold-induced
MT depolymerisation. After 1 min recovery of cells at
37°C the initial average spindle MT length of approxi-
mately 1 μM in metaphase cells was not different
between all experimental conditions (untreated, vehicle-
treated, pitstop 2, MLN8237, dynole 34–2, CHC and
epsin siRNA) (Additional file 5: Figure S5A). However,
in CHC-depleted cells and in cells treated with
MLN8237 MT regrowth was significantly impaired after
5 min recovery (Figure 4A-C) and TACC3 spindle
localization was severely disrupted (Additional file 6:
Figure S6). In contrast, regrowth rates were unaffected
in cells treated with pitstop 2, dynole 34–2 or epsin
siRNA (Figure 4A-C) and the localization of CHC
(Figure 1C) and TACC3 (Additional file 6: Figure S6) at
the mitotic spindle was also unaffected. After 30 min
regrowth, the length of the MTs in CHC-depleted cells
and in cells treated with MLN8237 was comparable to
control cells (Additional file 5: Figure S5B) indicating
that reformation of the mitotic spindle is not abolished
but slowed. MT regrowth from interphase centrosomes
that generate non-mitotic spindle fibres was not
disrupted by any experimental condition (Additional file
7: Figure S7). This is consistent with the lack of MT
localization during interphase and a role for CHC and
Aurora A kinase in regulating MTs during this stage of
the cell cycle. Since the TD is not required for MT
regrowth, these observations clearly support the above
data that pitstop 2 action is most likely mediated by the
TD. The data shows that the action of pitstop 2 on
mitotic spindle integrity is occurring after the stage of
clathrin recruitment specifically to spindle MTs by an as
yet unknown key spindle protein.
Pitstop 2 activates the spindle assembly checkpoint
The SAC is activated when the K-fibres of the mitotic
spindle have not attached correctly to the KTs that are
associated with the centromeres of the chromosomes
[2]. Since pitstop 2 disrupts K-fibres (Figure 2) we next
asked whether pitstop 2 activates the SAC. BubR1 is a
SAC protein that is phosphorylated on S676 and loca-
lizes to KTs upon SAC activation [34]. We quantified
the fluorescence intensity of phospho-BubR1 at the spin-
dle as a ratio of phospho-BubR1 on the chromosomes:
whole cell. Pitstop 2, MLN8237, depletion of CHC or
depletion of epsin all significantly increased the level of
phospho-BubR1 at the spindle (Figure 5A-C). This indi-
cates that the SAC is activated under these experimental
conditions while dynole 34-2 did not activate the SAC.
To independently confirm that pitstop 2 activates the
SAC we quantified the level of MAD2 localisation to the
Figure 1 (See legend on next page.)
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Figure 1 Pitstop 2 disrupts the mitotic spindle and impairs mitotic progression. A-B, Asynchronously growing HeLa cells were treated with
the indicated concentration of pitstop 2, 0.1% DMSO vehicle, or 0.3 μM MLN8237 for 6 h (A). Asynchronously growing CHC-depleted cells were
treated with pitstop 2 (30 μM), dynole 34-2 (30 μM), MLN8237 (0.3 μM) or DMSO vehicle (0.1%) for 6 h (B). Graphs show the percentage of cells
in metaphase (mitotic index, mean ± S.E.M. from two independent experiments, n≥300 per sample). (C) Representative microscopy images of
G2/M-synchronized HeLa cells after 30 min treatment with pitstop 2 (30 μM), dynole 34-2 (30 μM), MLN8237 (0.3 μM) or DMSO vehicle (0.1%).
Images of untreated, CHC-depleted and epsin-depleted G2/M-synchronized cells are also shown. Alpha-tubulin (red); CHC (green); DNA (blue).
D-E, Graphs (mean ± S.E.M. of two independent experiments; n≥30 per sample) show the percentage of metaphase cells with a narrow mitotic
spindle in (D) cells described in C as well as in (E) untreated, CHC-depleted, epsin-depleted G2/M-synchronized and in CHC-depleted cells treated
with pitstop 2 (30 μM), dynole 34-2 (30 μM), MLN8237 (0.3 μM), or DMSO vehicle (0.1%) for 30 min following G2/M synchronization. F-G, Dot
blots show the ratio of the width of the mitotic spindle/total cell of metaphase cells quantified in (D) and (E). Pitstop 2 assessed at 30 μM. Each
dot represents one cell. Solid black line represents median (n≥2, 30 cells per sample). Statistical significance determined by Student’s t-test
(* p < 0.05, ** p < 0.01).
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and is released once the checkpoint is satisfied [43,44].
The chromosomal localisation of MAD2 significantly
increased following treatment with pitstop 2, MLN8237,
CHC siRNA or epsin siRNA (Figure 5D and E). We con-
clude that pitstop 2 activates the SAC in an analogous
manner to the Aurora A kinase inhibitor MLN8237.
Pitstop 2 induces apoptosis and inhibits cell growth in
dividing cancer cells
Mitotic inhibitors such as MLN8237 [5] which acti-
vate the SAC have anti-cancer properties due to their
ability to inhibit cell proliferation and induce cell
death following prolonged SAC activation [3,4]. We
previously showed that pitstop 2 does not induce cell
death in HeLa cells after an acute treatment for sev-
eral hours [28]. However, those experiments were
performed on asynchronously growing cells whereby
only ~3% of cells are dividing at any given time and
were specifically designed to show that the com-
pound is not inherently cytotoxic. In contrast, we
next set out to ask whether pitstop 2 will inhibit cell
proliferation and induce cell death in mitotically div-
iding cells following a prolonged metaphase arrest, as
occurs for other SAC activators. We first determined
if pitstop 2 is cytotoxic and if this is selective for div-
iding cells by performing a lactate hydrogenase
(LDH) release assay to assess membrane integrity,
which is indicative of cell viability. After an acute
20 h treatment, dynole 34–2 is cytotoxic to cells in a
dose-dependent manner, and toxicity increases sig-
nificantly in dividing cells (Figure 6A), as previously
shown [37]. Our previous report indicates that this
cellular cytotoxicity occurs following cytokinesis fail-
ure. Specifically, dynole 34–2 caused cell death in
G2/M synchronized HeLa cells at concentrations as
low as 3 μM, but the equivalent induction of cell
death was only evident at concentrations ≥30 μM in
asynchronously growing cells (Figure 6A). Even after
a 20 h exposure to pitstop 2, asynchronously growing
HeLa cells were relatively resistant to this compoundwith <8% cell death at concentrations as high as
100 μM (Figure 6A), consistent with our previous re-
port [28]. Pitstop 2 or MLN8237 exhibited analogous
effects. G2/M synchronized HeLa cells were signifi-
cantly more sensitive to either agent, with >21%
(pitstop 2) of these cells undergoing cell death at
concentrations as low as 3 μM (Figure 6A).
We next sought to determine if pitstop 2 also possessed
anti-proliferative properties by scoring the total viable cell
number using a trypan blue exclusion assay. G2/M synchro-
nized HeLa cells were treated for 24 h immediately follow-
ing release from the G2/M block. The total number of
viable HeLa cells following pitstop 2, MLN8237 or dynole
34–2 treatment was markedly reduced in a dose-dependent
manner (Figure 6B). At high concentrations of pitstop 2
(30 μM) the total viable cell number was less than the num-
ber of cells scored immediately prior to administration of
the compound (dashed line). This indicates that pitstop 2
not only inhibits cell proliferation but also causes cell death.
This was also evident following MLN8237 and dynole 34–2
treatment (Figure 6B). Taken together this indicates that
pitstop 2 blocks proliferation and causes a much greater
rate of cell death in dividing cells than non-dividing cells.
Pitstop 2-induced cell death was due to apoptosis
since it was accompanied by an increase in PARP
cleavage following a 24 h treatment (Figure 6C and
D). PARP was also cleaved in cells treated with
MLN8237, dynole 34-2 or following exposure to
ultraviolet irradiation (UV; Figure 6C and D). Finally,
we compared the growth of HeLa cells with non-
tumourigenic fibroblasts, NIH3T3. While pitstop 2
blocked proliferation and induced cell death in G2/
M-synchronized HeLa cells after 48 h (whereby cells
were treated every 24 h, Figure 7A), the compound
had no significant effect in NIH3T3 cells (Figure 7B).
Collectively, these findings indicate that pitstop 2 has
anti-proliferative and cytotoxic properties that appear
to be relatively selective for dividing cancer cells.
Thus, pitstop 2 is a new member of anti-mitotic
compounds that causes mitotic arrest and SAC acti-
vation, with clathrin being the novel target.
Figure 2 Pitstop 2 disrupts chromosome congression and K-fibre organization during metaphase. A-B, Metaphase synchronized HeLa
cells were treated with the indicated siRNA either alone or in combination with pitstop 2 (30 μM), dynole 34-2 (30 μM), MLN8237 (0.3 μM), or
DMSO (0.1%) (A) or with the indicated drug alone (B). The graph shows the width of the metaphase plate in each experimental condition, where
each dot represents a cell (n≥2 30 cells were scored per sample). Median is indicated by the solid black line. Statistical significance was
determined by a Student’s t-test (* p < 0.05, ** p < 0.01). C-E, Metaphase synchronized HeLa cells treated with the indicated siRNA or drugs were
stained for α-tubulin (red), HURP (green), and DNA (DAPI, blue). Representative immunofluorescence microscopy images are shown in (C). The
graphs (mean ± S.E.M.; n≥30 per sample) show the percentage of siRNA-treated (D) and drug-treated (E) cells with abnormal HURP localisation.
Statistical significance was determined using a Student’s t-test (* p < 0.05, ** p < 0.01).
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Figure 3 Pitstop 2 induces multipolar spindle formation and loss of centriole cohesion. A, Representative immunofluorescence microscopy
images of metaphase synchronized CHC-depleted HeLa cells or HeLa treated with pitstop 2 (30 μM), dynole 34-2 (30 μM), MLN8237 (0.3 μM) or
DMSO vehicle (0.1%) showing the centrosomes (centrin 2, red) surrounded by the PCM (γ-tubulin, green). DNA shown in blue. Inset shows a
zoomed in image of the centrosomes. B-E, HeLa cells treated with the indicated drugs (B and D) or siRNA (C and E) described in (A) were scored
for the presence of multipolar spindles (B and C) and the poles of these spindles were scored for the number of centrioles per PCM (D and E).
The graphs (mean ± S.E.M. of two independent experiments; n≥30 per sample) show the percentage of cells with these characteristics. The x-axis
in D and E represent the number of centrioles per spindle pole in each metaphase cell. Statistical significance was determined by a Student’s
t-test (* p < 0.05, ** p < 0.01).
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Figure 4 Pitstop 2 does not affect microtubule nucleation from the mitotic spindle poles. A, Metaphase synchronized HeLa cells were
treated as described in Figure 2C then subjected to a MT regrowth assay whereby the MTs were allowed to regrow for 5 mins following
depolymerization. Cells were fixed and stained for γ-tubulin (green), α-tubulin (red), and DNA (DAPI, blue). B-C, The dot blots show the length of
the longest MT grown from each spindle pole in HeLa cells treated with the indicated siRNA (B) or drugs (C) as described in A. The median MT
length in each experimental condition is indicated by the solid black line. n≥30 per sample. Statistical significance was determined by a Student’s
t-test (* p < 0.05, ** p < 0.01).
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Clathrin plays a non-endocytic function during mitosis
that is downstream of the Aurora A kinase [38]. Inhibi-
tors of Aurora A are currently being assessed in human
clinical trials of cancer with promising success [5]. Here,
we used the first clathrin inhibitor, pitstop 2, to illustrate
that clathrin is also a valid target for the development of
inhibitors that (i) are useful molecular tools to assess
clathrin function and (ii) have the potential to be anti-cancer agents. Pitstop 2 induced mitotic phenotypes
consistent with inhibition of clathrin, which included an
increase in the mitotic index and width of the metaphase
plate, loss of K-fibres and mitotic spindle integrity,
chromosome mis-alignment and activation of the SAC.
In an analogous manner to the Aurora A inhibitor,
MLN8237, pitstop 2 inhibited cell proliferation and
induced cell death exclusively in dividing cancer cells.
Non-tumourigenic fibroblasts were not affected by this
Figure 5 Pitstop 2 activates the SAC. A, Metaphase synchronized HeLa cells were treated as described in Figure legend 2C then fixed and
stained for phospho-BubR1S676(green), α-tubulin (red) and DNA (DAPI, blue). Representative immunofluorescence microscopy images show that
the amount of phospho-BubR1S676 on the chromosomes increases following treatment with pitstop 2, MLN8237, and following depletion of CHC
or epsin. B-C, The dot blots show the fluorescence intensity ratio of BubR1S676 on the chromosomes/whole cell in individual HeLa cells treated
with the indicated drugs (B) or siRNA (C). D-E, Metaphase synchronized HeLa cells were treated and processed as described in A except that they
were stained for MAD2 instead of BubR1S676. The dot blots show the fluorescence intensity ratio of MAD2 on the chromosomes/whole cell in
individual HeLa cells treated with the indicated drugs (B) or siRNA (C). The median fluorescence intensity ratio in all dots blots shown is indicated
by the solid black line. n≥30 per sample from two independent experiments. Statistical significance was determined by a Student’s t-test
(* p < 0.05, ** p < 0.01).
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Figure 6 Pitstop 2 causes cell death and inhibits cell growth in dividing cells. A, Asynchronously growing and G2/M-synchronized HeLa
cells were subject to an LDH assay following a 20 h treatment with increasing concentrations of pitstop 2, dynole 34-2 and MLN8237. The graph
shows the amount of LDH in each experimental condition, as an indicator of cellular cytotoxicity, which was calculated as a percentage of total
cell lysis. B, G2/M-synchronized HeLa cells were exposed to increasing concentrations of dynole 34-2, MLN8237 and pitstop 2 for 24 h. Total
viable and non-viable cell number (mean ± S.D. from two independent experiments) were assessed by trypan blue. C, Cells were treated as
described in B. Lysates were collected and immunoblotted for cleaved PARP. HeLa cells exposed to UV served as a positive control. Actin served
as a loading control. D, Quantitative densitometric analysis of cleaved PARP levels shown in C. Graph (mean ± S.E.M. from five independent
experiments) shows the relative amount of PARP in HeLa cells following treatment with the indicated conditions that have been normalised to
background.
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Figure 7 Pitstop 2 does not affect the growth and viability of
non-tumourigenic NIH3T3 fibroblasts. A-B, HeLa (A) and NIH3T3
(B) cells were synchronized in mitosis and then treated with
increasing concentrations of the indicated compounds at 24 h
intervals. After 48 h, total viable and non-viable cell number
(mean ± S.D. from two independent experiments) was assessed by
trypan blue. Drug concentrations are indicated in μM units.
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TD inhibitor, pitstop 2, possesses anti-mitotic and anti-
cancer properties consistent with other SAC activating
compounds.
We confirm the mitotic role of clathrin in maintaining
integrity of the mitotic spindle by stabilizing K-fibres.
However, we reveal an additional mitotic role for cla-
thrin in maintaining spindle pole integrity by participat-
ing in centriole cohesion. Depletion of CHC and pitstop
2 treatments caused an increase in the number of multi-
polar spindles whereby the spindle poles frequently con-
tained only one centriole. Cyclin G-associated kinase
(GAK) is a binding partner of CHC and required for
CME [45]. Like CHC, it has recently been reported to
also function during metaphase in an endocytic-
independent manner for correct chromosome segrega-
tion. Like CHC, GAK localizes to the mitotic spindle
and GAK-depleted cells phenocopy the mitotic defects
induced by depletion of CHC [46]. One of the mitotic
phenotypes observed in GAK-depleted cells is the pres-
ence of multipolar spindles that contain only one centri-
ole at the spindle pole. It was proposed that this
phenotype was due to microtubule forces, as mis-aligned
chromosomes would generate pushing and pulling forces
on the mitotic spindle resulting in fragmentation of the
spindle poles. CHC is lost from the mitotic spindle in
GAK-depleted cells [46] and thus a similar hypothesis
could also explain the loss of centriole cohesion
observed in CHC-depleted and pitstop 2–treated cells.
Therefore CHC appears to play an indirect role in main-
taining spindle pole integrity and centriole cohesion via
its role in bridging K-fibres for correct chromosome
congression and segregation.
The mitotic spindle localization of clathrin was not
perturbed by pitstop 2. This was surprising given that
pitstop 2 binds the TD of CHC [28], which is within the
N-terminal region of clathrin known to be required for
its mitotic spindle localization [11,21]. The crystal struc-
ture of the CHC-TD (residues 1–364) reveals a classical
seven-bladed β-propeller that contains a clathrin-box
LφXφ [DE] (where φ is a bulky hydrophobic amino acid,
X is any and brackets enclose alternatives) and W-box
motifs for association with binding partners [47,48],
however some proteins may bind to other blades of the
TD such that there may be up to 4 separate protein
interaction sites in the TD [49]. Pitstop 2 docks into the
cleft comprising the clathrin-box between blades 1 and 2
of the β-propellor [28]. Clathrin does not bind MTs dir-
ectly, suggesting that clathrin is tethered to the mitotic
spindle via other interactions that may involve other
parts of clathrin such as the W-box. In support of this
idea, phospho-TACC3 binds CHC via its linker domain
and first CHC repeat and does not appear to require the
TD of clathrin [13]. B-Myb [50] and GAK [46] havebeen implicated in recruiting clathrin to the mitotic
spindle and thus represent potential W-box binding
partners during mitosis. Clathrin is thought to recruit
TACC3 to the mitotic spindle via interactions that do
not dependent on the TD [13]. Consistent with this idea,
we show that in contrast to depletion of CHC, pitstop 2
does not affect TACC3 recruitment to the mitotic spin-
dle. Nor does it impair microtubule regrowth and initi-
ation of mitotic spindle formation, which is in contrast
to that caused by depletion of CHC. Thus, pitstop 2 does
not induce an aberrant mitotic phenotype by blocking
recruitment of clathrin to the mitotic spindle but rather
appears to inhibit clathrin function once it is stationed
at the spindle.
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MLN8237, are being developed as a new class of anti-
cancer agents due to their ability to prolong metaphase ar-
rest and subsequently inhibit cell proliferation and induce
cell death in dividing cancer cells [3,4]. As a result, many of
these targeted inhibitors reduce tumour volume in vivo [3]
and are being assessed in cancer clinical trials [5]. We show
that pitstop 2 possesses anti-cancer properties since it
phenocopies SAC activating compounds like MLN8237 or
CHC knockdown. Aurora A mediates its function through
many other proteins in addition to clathrin and therefore
Aurora A inhibitors induce a plethora of phenotypes [51].
This could potentially result in unwanted side effects and
reduced efficacy for cancer patients. Therefore, we predict
that clathrin TD inhibitors may be more targeted, raising
the opportunity for them to be potentially more efficacious
compounds for the treatment of cancer. Pitstop 2 was not
as potent as MLN8237 at inducing aberrant mitotic pheno-
types, inhibiting cell proliferation and inducing cell death,
and new generation analogues are required. Our findings
provide proof-of-concept that clathrin is a valid target for
the development of small molecule inhibitors that can be
exploited as new strategies to design anti-cancer therapeu-
tics. Pitstop 2 therefore represents a new lead compound
amenable to drug development.
Additional files
Additional file 1: Figure S1. Structures of compounds. The chemical
structures of pitstop 2 (A), MLN8237 (B) and dynole 34-2 (C).
Additional file 2: Figure S2. Depletion of CHC or epsin. Cells were
depleted of the indicated protein by siRNA for 72 hours. Lysates were
collected and immunoblotted for CHC, epsin and γ-tubulin. CHC and
epsin siRNAs caused a >90% depletion of the target protein.
Additional file 3: Figure S3. Schematic illustration of the time-line of
experimental procedures.
Additional file 4: Figure S4. Effect of pitstops on endocytosis. A
quantitative high-throughput endocytosis assay using Texas Red-Tfn
uptake in HeLa cells pre-treated with increasing concentrations of pitstop
2 and dynole 34-2 for 30 min. Data are expressed as mean ± 95%
confidence intervals (CI) for triplicates and ~1200 cells. Similar results
were obtained in three independent experiments.
Additional file 5: Figure S5. Microtubule regrowth in mitotic cells. A-B,
Metaphase-synchronized HeLa cells were treated with the indicated
drugs (left) or siRNA (right) then subjected to a MT regrowth assay after
30 min cold exposure, whereby the MTs were allowed to regrow at 37°C
for 1 min (A) and 30 min (B) following depolymerization. Cells were fixed
and stained for γ-tubulin (green), α-tubulin (red), and DNA (DAPI, blue).
The dot blots show the length of the longest MT grown from each
spindle pole in HeLa cells treated with the indicated drugs (left) or siRNA
(right). The median MT length in each experimental condition is
indicated by the solid black line. n ≥ 30 per sample. Statistical
significance was determined by a Student’s t-test (* p < 0.05, ** p < 0.01).
Additional file 6: Figure S6. TACC3 recruitment is not affected by
pitstop compounds. A, Metaphase synchronized HeLa cells treated with
the indicated siRNA or drugs were stained for TACC3 (green), α-tubulin
(red), and DNA (DAPI, blue). Representative immunofluorescence
microscopy images illustrate that that MLN8237 and CHC siRNA
treatment decreases TACC3 recruitment to the mitotic spindle. B-C,
Quantitation of data described in A. The dot blots show the fluorescenceintensity ratio of TACC3 on the mitotic spindle/whole cell in individual
HeLa cells treated with the indicated drugs (B) or siRNA (C). The median
fluorescence intensity ratio in all dots blots shown is indicated by the
solid black line. n ≥ 30 per sample. Statistical significance was
determined using a Student’s t-test (* p < 0.05, ** p < 0.01).
Additional file 7: Figure S7. Effect of pitstop 2 on microtubule
regrowth in interphase cells. A-B, Asynchronously growing HeLa cells
were treated with the indicated compounds (left) and siRNA (right) then
subjected to a MT regrowth assay whereby the MTs were allowed to
regrow for 1 min (A) and 5 min (B) at 37°C following a cold
depolymerization. Cells were fixed and stained for γ-tubulin (green), α-
tubulin (red), and DNA (DAPI, blue). The dot blots show the length of the
longest MT grown from each centrosome in HeLa cells in interphase
treated with the indicated drugs (left) or siRNA (right). The median MT
length in each experimental condition is indicated by the solid black line.
n ≥ 30 per sample. Statistical significance was determined by a Student’s
t-test (* p < 0.05, ** p < 0.01).
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